Sponsor
Gabe Evans
Representative · R-CO
Representative · R-CO
Defines pill-form counterfeit fentanyl/methamphetamine, modifies federal drug statute scope, requires a DEA response plan within 180 days, and mandates annual DOJ reporting on seizures and prosecutions.
The bill strengthens enforcement, data collection, and public-awareness efforts to remove deadly counterfeit fentanyl/meth pills and reduce overdoses, but it increases prosecution risk, compliance and administrative costs, and may prioritize enforcement over public-health approaches.
Law enforcement and prosecutors (and thus the public) will have clearer authority to investigate and prosecute sellers who market fentanyl- or methamphetamine-laced pills as legitimate products, improving the ability to remove deadly counterfeit pills from circulation.
Children, teens, young adults, and other at-risk people will receive expanded, data-informed education and prevention messaging that can reduce accidental overdoses from counterfeit fentanyl and methamphetamine pills.
Local governments, public-health partners, and law enforcement will gain access to annual aggregated federal data on counterfeit fentanyl/meth pills, improving transparency and helping target local prevention and response efforts.
People who use drugs, especially young and low-income users, will face greater risk of criminalization because broader definitions and stronger enforcement make possession or distribution prosecutions more likely even when intent to counterfeit is unclear.
Taxpayers and federal agencies will bear higher costs because strengthened enforcement, expanded reporting, and public-awareness campaigns require additional DEA/DOJ/ONDCP resources and administrative burden.
Law enforcement agencies and federal employees could have active investigations or prosecutorial strategies exposed if published data are too detailed or nondisclosure exceptions are insufficient.
Based on analysis of 5 sections of legislative text.
Official title: To amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances, and for other purposes.
Introduced March 19, 2026 by Gabe Evans · Last progress March 19, 2026
Creates a new federal definition for "counterfeit fentanyl or methamphetamine substance," modifies federal criminal statutory language related to illegal distribution, requires the DEA to deliver an operational response plan within 180 days to address pill-form counterfeit fentanyl/methamphetamine (including enforcement, education, and public-awareness audits), and requires the Attorney General to provide Congress with annual aggregated reports on seizures, identifications, prosecutions, and prevention efforts (first report due within one year). The law focuses on strengthening enforcement, improving prevention and public-awareness campaigns aimed at youth, and improving reporting and data about pill-form counterfeit drugs.